CanSino Biologics Inc.

CanSino's Inhaled TB Booster Vaccine Advances with Clinical Trial Approval in Indonesia

6 days ago

• CanSino Biologics has received clinical trial approval in Indonesia for its innovative inhaled tuberculosis booster vaccine, marking a significant advancement in TB prevention strategies. • The inhaled delivery system represents a novel approach to tuberculosis vaccination, potentially offering advantages over traditional injection methods in terms of administration and efficacy. • This development comes amid global efforts to combat tuberculosis, which remains one of the world's deadliest infectious diseases despite existing prevention measures.

CanSino Biologics Initiates Phase I/II Trial of Recombinant Polio Vaccine in Indonesia

5 months ago

• CanSino Biologics has commenced a Phase I/II clinical trial in Indonesia for its Recombinant Poliomyelitis Vaccine (CS-2036). • The CS-2036 vaccine utilizes a non-infectious polio VLP, potentially offering enhanced safety and immunogenicity. • This trial aims to assess the safety and immunogenicity of CS-2036 in infants and toddlers within specific age groups. • The WHO recommends non-infectious polio VLP-based vaccines as a preferred option post-polio eradication.

CanSino Biologics Initiates Phase II/III Trial for Tdcp Adolescent and Adult Vaccine

5 months ago

• CanSino Biologics has commenced a Phase II/III clinical trial for its Tdcp Adolescent and Adult vaccine, targeting individuals aged six years and older. • The Tdcp vaccine is designed as a booster for diphtheria, tetanus, and pertussis, addressing a gap in the Chinese market where no approved booster exists for adolescents and adults. • The vaccine utilizes separately purified pertussis antigens, formulated in a defined ratio to ensure consistent product quality and enhanced stability. • Successful development of this vaccine aims to fill the domestic market void, aligning China with routine vaccination programs in major developed countries.